201920182017201620152014 December 04, 2019 Summary ToggleSpero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease November 29, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 26, 2019 Summary ToggleSpero Therapeutics to Host Key Opinion Leader Symposium in December November 04, 2019 Summary ToggleSpero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review October 31, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 03, 2019 Summary ToggleSpero Therapeutics Announces Positive Recommendation to Continue Phase 3 Clinical Trial of SPR994 as Planned Following Independent Review Committee Analysis of SPR994 Treated Patients in Lead-in Cohort of Trial September 30, 2019 Summary ToggleSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 26, 2019 Summary ToggleSpero Therapeutics Announces Presentations at IDWeek 2019 August 08, 2019 Summary ToggleSpero Therapeutics Announces Second Quarter 2019 Operating Results and Provides Pipeline Update July 16, 2019 Summary ToggleSpero Therapeutics Announces $5.9 Million Award from U.S. Department of Defense to Further Clinical Development of SPR206 Pagination Current page 1 Page 2 Page 3 Next page Next Last page Last
